Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
1. Bristol Myers and Pfizer offer Eliquis at discounted rates for cash-paying patients. 2. This new program could enhance patient access and sales growth for BMY.
FAQ
Why Bullish?
The direct availability of Eliquis at a discounted rate may boost sales volumes. The precedent set by similar programs shows a positive correlation with revenue increases in pharmaceutical companies.
How important is it?
The shift to improved access for Eliquis directly influences BMY's market competitiveness and could lead to increased revenue. The scalability of this initiative demonstrates the company’s proactive approach to market challenges.
Why Short Term?
The discount program may lead to immediate increases in patient access and sales. Historical instances of similar initiatives have shown time-sensitive impacts on revenue.